Chart Events
Performance Outlook
| Previous Close | 14.01 |
| Open | 14.10 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 13.99 - 14.12 |
| 52 Week Range | 12.48 - 18.43 |
| Volume | 122,568 |
| Avg. Volume | 87,433 |
| Market Cap | 26.447B |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | 16.45 |
| EPS (TTM) | 0.85 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.37 (2.66%) |
| Ex-Dividend Date | Mar 27, 2020 |
| 1y Target Est | N/A |
- PR Newswire
U.S. FDA Grants Fast Track Designation for ASP0367/MA-0211, a Selective PPARδ Modulator being Developed for the Treatment of Primary Mitochondrial Myopathies
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas" ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of ASP0367/MA-0211 ("ASP0367") as a potential treatment for primary mitochondrial myopathies (PMM).
- PR Newswire
New Roxadustat Data in Anemia of Chronic Kidney Disease to be Released at ASN Kidney Week 2020 Reimagined
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, PhD, "Astellas") today announced that in collaboration with FibroGen and AstraZeneca, 42 roxadustat abstracts will be presented at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined congress.
- Moody's
Astellas Pharma Inc. -- Moody's announces completion of a periodic review of ratings of Astellas Pharma Inc.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Astellas Pharma Inc. Tokyo, August 27, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Astellas Pharma Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
